Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -1.18 is 98% above its 5-year average of -54.06, near the high end of its 5-year range (-103.63–2.61).
73.18% above its 12-month average of -4.40.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.32.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T13:25:31.106Z. Historical observations retain their original dates. Historical series through 2026-05-12.
EARNINGS PER SHARE (EPS)
-1.18
EARNINGS PER SHARE (EPS) AVG TTM
-4.40
EARNINGS PER SHARE (EPS) AVG 3Y
-32.48
EARNINGS PER SHARE (EPS) AVG 5Y
-54.06
EARNINGS PER SHARE (EPS) AVG 10Y
-74.77
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+73.18%
CURRENT VS 3Y AVG
+96.37%
CURRENT VS 5Y AVG
+97.82%
CURRENT VS 10Y AVG
+98.42%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Atara Biotherapeutics, Inc.
Market Cap
$84.70M
Earnings Per Share (EPS)
-1.18
TTM Avg
-4.40
3Y Avg
-32.48
5Y Avg
-54.06
Market Cap
$84.75M
Earnings Per Share (EPS)
-1.88
TTM Avg
-2.06
3Y Avg
-2.07
5Y Avg
-1.66
Market Cap
$84.00M
Earnings Per Share (EPS)
-0.51
TTM Avg
-0.76
3Y Avg
-0.68
5Y Avg
-1.48
Market Cap
$83.96M
Earnings Per Share (EPS)
-0.19
TTM Avg
-0.58
3Y Avg
-0.69
5Y Avg
-0.67
Market Cap
$83.49M
Earnings Per Share (EPS)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$86.69M
Earnings Per Share (EPS)
0.07
TTM Avg
-0.09
3Y Avg
-1.24
5Y Avg
-1.25
Market Cap
$87.86M
Earnings Per Share (EPS)
-0.60
TTM Avg
-0.82
3Y Avg
-0.86
5Y Avg
-0.88
Market Cap
$81.22M
Earnings Per Share (EPS)
-0.48
TTM Avg
-0.32
3Y Avg
-0.23
5Y Avg
-0.23
Market Cap
$88.21M
Earnings Per Share (EPS)
0.08
TTM Avg
-0.19
3Y Avg
-0.36
5Y Avg
-0.27
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | $84.70M | -1.18 | -4.40 | -32.48 | -54.06 |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $84.75M | -1.88 | -2.06 | -2.07 | -1.66 |
| Humacyte, Inc. (HUMA)vs › | $84.00M | -0.51 | -0.76 | -0.68 | -1.48 |
| Cognition Therapeutics, Inc. (CGTX)vs › | $83.96M | -0.19 | -0.58 | -0.69 | -0.67 |
| Conexeu Sciences Inc. (CNXU)vs › | $83.49M | N/A | N/A | N/A | N/A |
| CareCloud, Inc. (CCLD)vs › | $86.69M | 0.07 | -0.09 | -1.24 | -1.25 |
| Cardiff Oncology, Inc. (CRDF)vs › | $87.86M | -0.60 | -0.82 | -0.86 | -0.88 |
| Citius Oncology, Inc. (CTOR)vs › | $81.22M | -0.48 | -0.32 | -0.23 | -0.23 |
| ImmuCell Corporation (ICCC)vs › | $88.21M | 0.08 | -0.19 | -0.36 | -0.27 |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $79.46M | -1.17 | -2.88 | -6.48 | -4.74 |
Trailing EPS (TTM)
$-1.18
Forward EPS (Est.)
$-0.69
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | 2.61 |
| 2024-12-31 | -11.41 |
| 2023-12-31 | -65.18 |
| 2022-12-31 | -55.96 |
| 2021-12-31 | -90.78 |
| 2020-12-31 | -103.63 |
| 2019-12-31 | -141.78 |
| 2018-12-31 | -131.64 |
| 2017-12-31 | -100.03 |
| 2016-12-31 | -68.78 |
| 2015-12-31 | -55.92 |
| 2014-12-31 | -140.42 |
| 2013-12-31 | -227.09 |
| 2012-12-31 | -16.81 |
